Quantum-Si’s Post

𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐚𝐧𝐝 𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐓𝐫𝐞𝐧𝐝𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐌𝐢𝐜𝐫𝐨𝐚𝐫𝐫𝐚𝐲 𝐊𝐢𝐭𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 » 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 : https://lnkd.in/eQdfsNEf The latest report from Meticulous Research® projects the microarray kits market will grow to $2.51 billion by 2031, with a CAGR of 5.8% from 2024. Key factors driving this growth include the increasing applications of microarrays in cancer and other areas of biomedical research, alongside rising adoption of personalized medicine. The pharmaceutical and biotech industries, both investing heavily in R&D, are playing a significant role in boosting demand for #microarray_kits. Technological advancements open new avenues for microarray technology, especially in emerging markets where investment in life sciences is increasing. However, challenges like limited sensitivity and accuracy in certain applications persist, and high costs compared to other testing methods could impede market expansion. » 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 : Thermo Fisher Scientific, Illumina, Agilent Technologies, Merck Group, PerkinElmer, QIAGEN N.V., Edvotek Inc, Sakura Finetek Europe , Dextra Group, GeneCopoeia.   » 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 : • 𝗡𝗲𝘂𝗿𝗼𝗺𝗼𝗱𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗦𝘆𝘀𝘁𝗲𝗺𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 : https://lnkd.in/durzqeWc • 𝗩𝗲𝘁𝗲𝗿𝗶𝗻𝗮𝗿𝘆 𝗩𝗮𝗰𝗰𝗶𝗻𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 : https://lnkd.in/dV2HS5Xx • 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 : https://lnkd.in/d4tRZYXH   #MicroarrayKits #GenomicResearch #BiotechInnovation #DNAAnalysis #GeneExpression #MolecularDiagnostics #HighThroughputScreening #OmicsTechnology #PersonalizedMedicine #CancerResearch #PharmaceuticalDevelopment #Bioinformatics #LaboratoryEquipment #ResearchTools #BiologicalSciences #GenomeMapping #MicroarrayTechnology #ClinicalResearch #GeneticTesting #LifeS ciences

Today, TrialKey attended the BioConnect: Australia-Taiwan Biotech Forum at the Centre for Eye Research Australia (CERA), hosted by Southern Taiwan Science Park, the Development Center for Biotechnology, and Australian Trade and Investment Commission (Austrade). The event brought together 12 pioneering Taiwanese biotech companies, including ACRO Biomedical Co., Ltd., KriSan Biotech Co., Ltd., and UNICOCELL Biomed, each advancing innovative solutions from regenerative medicine to RNA therapeutics. TrialKey had the opportunity to engage in one-on-one meetings with these companies, showcasing our AI-powered biostatistical validation and clinical trial simulation services. This experience underscored our commitment to bridging international clinical research partnerships and exploring collaborative synergies. Book a demo: https://appt.link/minhthu Marketing and Opyl investor enquiries: bernice@trialkey.ai #biotechnology #clinicalresearch #biotech #medtech #healthtech #regenerativemedicine #australiabiotech #biostatistics #clinicaltrials #austrade #bioconnect #ai

Patent alert from GenNext Technologies! We are thrilled to share that GenNext Technologies has secured its inaugural Japanese Patent for the innovative Fox® Protein Footprinting technique. This patent safeguards our cutting-edge processes for conducting protein footprinting studies both in vitro, in vivo, and in-cell, underscoring our commitment to pioneering methodologies and exclusive instrumentation. With this milestone, GenNext solidifies its position as a leader in high-resolution protein footprinting, empowering researchers to enhance the development of safer, more efficient, and cost-effective therapeutics. A special thank you goes out to the dedicated GenNext Team whose unwavering dedication and inventive spirit have propelled structural biology research to new heights! #GenNext #Research #Science #ScientificResearch #Biotherapeutics #ProteinCharacterization #ResearchInnovation #HRPF #ProteinResearch #ScientificInnovation #Teamwork #ProteinStructure #StructuralBiology #Biochemistry #Proteomics #Biotechnology #Antibody #mAb

Patent alert from GenNext Technologies! We are thrilled to share that GenNext Technologies has secured its inaugural Japanese Patent for the innovative Fox® Protein Footprinting technique. This patent safeguards our cutting-edge processes for conducting protein footprinting studies both in vitro, in vivo, and in-cell, underscoring our commitment to pioneering methodologies and exclusive instrumentation. With this milestone, GenNext solidifies its position as a leader in high-resolution protein footprinting, empowering researchers to enhance the development of safer, more efficient, and cost-effective therapeutics. A special thank you goes out to the dedicated GenNext Team whose unwavering dedication and inventive spirit have propelled structural biology research to new heights! #GenNext #Research #Science #ScientificResearch #Biotherapeutics #ProteinCharacterization #ResearchInnovation #HRPF #ProteinResearch #ScientificInnovation #Teamwork #ProteinStructure #StructuralBiology #Biochemistry #Proteomics #Biotechnology #Antibody #mAb

𝗦𝗮𝘃𝗲 𝘁𝗵𝗲 𝗗𝗮𝘁𝗲 Join us for a webinar hosted by NEOsphere's Head of Mass Spectrometry and Founder, Uli Ohmayer, in collaboration with our technology partner, Bruker. 𝗨𝗻𝗹𝗼𝗰𝗸 𝘁𝗵𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗼𝗳 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗱𝗲𝗴𝗿𝗮𝗱𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗱𝗲𝗲𝗽 𝗽𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟱, 𝟮𝟬𝟮𝟰, 𝟭𝟬:𝟬𝟬 - 𝟭𝟭:𝟬𝟬 𝗮𝗺 𝗘𝗦𝗧, 𝟰:𝟬𝟬 - 𝟱:𝟬𝟬 𝗽𝗺 𝗖𝗘𝗧   Register to learn more about: - The combined power of the timsTOF HT and timsTOF Ultra 2, driving TPD proteomics applications to new heights. - NEOsphere's unparalleled high-throughput, scalable proteomics approach, utilizing label-free, single-shot DIA-PASEF mass spectrometry to identify novel degrader targets on a large scale with unmatched coverage, accuracy, and speed. - Slice-PASEF-based global ubiquitinomics, featuring an optimized acquisition strategy that verifies degrader-induced modifications with an unprecedented depth of 50,000 ubiquitination sites. - NEOverse, NEOsphere’s intuitive data analysis suite for fast, user-friendly evaluation and in-depth meta-analysis of large proteomic datasets, enabling target identification, SAR optimization, library expansion, and strategic drug discovery decisions. https://lnkd.in/dd2gbtyh Rohan Thakur, Scarlet Koch, Torsten Müller, Michael Greig, Dr. Bernd Müller, Christian Albers

Collaborations are essential for driving innovation and advancing scientific discoveries in #proteomics. Therefore, we’re excited to strengthen our collaboration with SCIEX.   This expanded partnership enables us to deliver even more cutting-edge, high-throughput proteomics solutions with greater flexibility and performance. The proven power of Evosep One with the advanced capabilities of the ZenoTOF 7600+, enable labs to process up to 500 samples per day with reduced system downtime. Tailored for robustness, this system minimizes sample carryover and maximizes data quality, making it an invaluable tool for advancing proteomics in pharma and biotechnology.   “Over the past 3 years, we are excited to see this collaboration grow to encompass more of the SCIEX portfolio. This latest achievement will allow scientist to harness the power of ZT Scan DIA data to precisely quantify proteins with up to 10-fold improvement in throughput for protein quantitation. Utilizing the Evosep One with SPD methods provides the speed and flexibility of analysis which perfectly matches with the performance of ZT Scan DIA. Together, SCIEX and Evosep can work together to help advance clinical proteomic research,” said Jose Castro-Perez, Vice President, Product Management.   Learn more in this recent press release from SCIEX: https://lnkd.in/dMYew8JY #pressrelease #scientificdiscoveries #technology #LCMS

𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐁𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐬 𝐢𝐧 𝐌𝐢𝐜𝐫𝐨𝐚𝐫𝐫𝐚𝐲 𝐊𝐢𝐭𝐬 𝐎𝐩𝐞𝐧 𝐍𝐞𝐰 𝐃𝐨𝐨𝐫𝐬 𝐢𝐧 𝐁𝐢𝐨𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 » 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 : https://lnkd.in/efktV-qJ The global market for #microarray_kits is expected to achieve significant growth, reaching $2.51 billion by 2031 at a 5.8% CAGR from 2024, as reported by Meticulous Research®. This growth is fueled by the increasing adoption of microarrays in research areas, particularly in cancer and personalized medicine. Pharmaceutical and biotech industries’ focus on research and development further bolsters market demand. Technological improvements in #microarray_technology and expansion opportunities in emerging economies present additional growth avenues. Nevertheless, high costs compared to other genetic testing options and certain performance limitations, such as sensitivity and accuracy, remain obstacles. The continued development in personalized medicine and ongoing tech innovations in microarrays are expected to help overcome these challenges and drive sustained market expansion.   » 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 : Thermo Fisher Scientific, Illumina, Agilent Technologies, Merck Group, PerkinElmer, QIAGEN N.V., Edvotek Inc, Sakura Finetek Europe , Dextra Group, GeneCopoeia.   » 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 : • 𝗡𝗲𝘂𝗿𝗼𝗺𝗼𝗱𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗦𝘆𝘀𝘁𝗲𝗺𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 : https://lnkd.in/durzqeWc • 𝗩𝗲𝘁𝗲𝗿𝗶𝗻𝗮𝗿𝘆 𝗩𝗮𝗰𝗰𝗶𝗻𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 : https://lnkd.in/dV2HS5Xx • 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 : https://lnkd.in/d4tRZYXH   #MicroarrayKits #GenomicResearch #BiotechInnovation #DNAAnalysis #GeneExpression #MolecularDiagnostics #HighThroughputScreening #OmicsTechnology #PersonalizedMedicine #CancerResearch #PharmaceuticalDevelopment #Bioinformatics #LaboratoryEquipment #ResearchTools #BiologicalSciences #GenomeMapping #MicroarrayTechnology #ClinicalResearch #GeneticTesting #LifeS ciences

VHH, or variable domain of heavy chain of IgG, refers to a unique type of antibody found in camelids such as llamas and camels. These antibodies possess remarkable properties, including small size, high stability, and exceptional binding specificity. By harnessing the power of VHH antibodies, researchers can target a wide range of antigens with precision and efficacy. Our #VHHLibraryConstruction service empowers researchers to tap into this vast potential by offering custom-built VHH libraries tailored to their specific needs. Whether you're investigating novel therapeutic targets, developing diagnostic assays, or exploring new avenues in biotechnology, our expert team is here to support your endeavors every step of the way. https://lnkd.in/gewEkHqE #KMDBioscience #VHHLibraryConstruction #AntibodyDiscovery #Biotechnology #Innovation #ResearchExcellence

𝐆𝐥𝐨𝐛𝐚𝐥 𝐌𝐢𝐜𝐫𝐨𝐚𝐫𝐫𝐚𝐲 𝐊𝐢𝐭𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐄𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐑𝐞𝐚𝐜𝐡 𝐍𝐞𝐰 𝐇𝐞𝐢𝐠𝐡𝐭𝐬 𝐛𝐲 𝟐𝟎𝟑𝟎 » 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 : https://lnkd.in/eQdfsNEf Meticulous Research® reports that the global microarray kits market is on track to reach $2.51 billion by 2031, growing at a CAGR of 5.8% from 2024 to 2031. The market’s robust growth is fueled by rising research applications of microarrays, a technology highly valued in cancer research and personalized medicine. Pharmaceutical and biotechnology sectors are also driving demand, investing heavily in R&D to advance precision healthcare solutions. Technological innovations in #microarray_technology present substantial growth potential, particularly in developing markets. These advancements could enhance accessibility and usability, enabling researchers to perform more accurate, reliable analyses. However, challenges like sensitivity limitations and relatively high costs persist, potentially slowing adoption rates in some areas. Despite these constraints, the adoption of personalized medicine and ongoing R&D investments are expected to sustain market growth.   » 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 : Thermo Fisher Scientific, Illumina, Agilent Technologies, Merck Group, PerkinElmer, QIAGEN N.V., Edvotek Inc, Sakura Finetek Europe , Dextra Group, GeneCopoeia.   » 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 : • 𝗡𝗲𝘂𝗿𝗼𝗺𝗼𝗱𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗦𝘆𝘀𝘁𝗲𝗺𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 : https://lnkd.in/durzqeWc • 𝗩𝗲𝘁𝗲𝗿𝗶𝗻𝗮𝗿𝘆 𝗩𝗮𝗰𝗰𝗶𝗻𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 : https://lnkd.in/dV2HS5Xx • 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 : https://lnkd.in/d4tRZYXH   #MicroarrayKits #GenomicResearch #BiotechInnovation #DNAAnalysis #GeneExpression #MolecularDiagnostics #HighThroughputScreening #OmicsTechnology #PersonalizedMedicine #CancerResearch #PharmaceuticalDevelopment #Bioinformatics #LaboratoryEquipment #ResearchTools #BiologicalSciences #GenomeMapping #MicroarrayTechnology #ClinicalResearch #GeneticTesting #LifeS ciences

Curious to learn about hit identification and high throughput screening strategies at Evotec? Join our 5-part webinar series now. The first 3 episodes are already available on demand, while new episodes in September and October are open for registration now. Overview of the episodes: #1: Unlocking High Throughput Hit Identification Strategies, with Thomas Ahrens #2: It All Starts With a Protein – Protein Sciences as a Key to Success in Drug Discovery, with James Errey #3: Molecular Interactions Matter - Biophysical Screening for Early Drug Discovery, with Florian Krieger #4: The Role of Structural Insights in Drug Discovery, with Jay Bertrand #5: Illuminating Cellular Processes through High Content Methods, with Karsten Kottig and Sven Schreiter To find more information, and to get access to the individual sessions, please visit: https://hubs.ly/Q02H5HRr0 #researchneverstops #Evotec #drugdiscovery